Novel artificial intelligence platform for drug development and personalized medicine
Our current applications
Our Services
HEALTH CARE ONCOLOGY WORKFLOW
HEALTH CARE ONCOLOGY WORKFLOW
- FDA Approved Drugs
- Medical indications
- Pharmacology toxicities
- Drugs interactions
- Ongoing clinical studies
- European and American guidelines
- Molecular Biomarkers for personalized medicine
- Real World Data
- Best workflow to reduce medical effort
PRECISION MEDICINE SOLUTIONS
PRECISION MEDICINE SOLUTIONS
- Genomic Molecular Alterations
- Evaluation of oncogenic molecular panels
- Druggable vulnerabilities
- Targered agents
- Therapeutic opportunities
- Drug combinations
- Ongoing clinical studies
- Identification of best treatment based on propietary algorithms
BIOMARKER AND DRUG DEVELOPER
BIOMARKER AND DRUG DEVELOPER
- Genomic molecular alterations
- Potential target inhibition
- Druggable vulnerabilities
- Current clinical development
- Competitive landscape
- Target population and indication
- Evaluation of attrition rate
- Pharma intelligent
- Identification of best clinical development
What we do
This platform uses data from different sources including molecular alterations, scientific results, clinical trials, combinations of compounds, described efficacy, competitive landscape, in addition to side effects or potential interactions, to provide the user with all relevant data in a customized manner, without the necessity to obtain this information through complex consulting dossiers.
In addition, we are developing algorithms that can help to predict the success of a new pharmacological compound through the identification of unmet necessities, empty areas, potential side effects or combinations that would not reach the clinical setting, as well as crowded sectors or areas for business development.
Request an online test
We would be happy to show you our platform.
Anglonordic 23 – London
April 20th. We are going to attend the 19th Annual Anglonordic Life Science Conference.Meet us to discuss face to face about our latest works: CA04 first-in-class monoclonal antibody, CA05 first-in-class kinase inhibitor and CA07 novel PROTAC.We can’t wait to hear...
Total funding raised Dec 2022
CancerAppy closed 2022 with €1.3M total raised.
CPP21 – InsilicoPROTACs
Cancerappy, together with UCLM, has been awarded the grant from the CCP21 program for the development of nanomedicines (nanoPROTACs), with a total budget of €757,000 and a project duration of 3 years.